Latest Article on Diabetes
The Future of Diabetes
Conversations Beyond Type 2 Diabetes
EFPIA Mission Possible
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
Links
Heart Talks
Heart Failure Matters
Downloads
Diabetic Retinopathy
Harold and Dorothy Patient Discussion Factsheet
Type 2 Diabetes
1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (accessed Jan 2019)